1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021 CA Cancer J Clin. 2021;71(1):7-33.
2. Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16(9):553-565.
3. The Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma Cancer Cell. 2017;32(2):185-203.
4. Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: A Review JAMA. 2021;326(9):851- 862.
5. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8):533-552.
6. Ma X, Lu J-Y, Dong Y, et al. PP6 Disruption Synergizes with Oncogenic Ras to Promote JNK-Dependent Tumor Growth and Invasion. Cell Rep. 2017;19(13):2657-2664.
7. Kishimoto K, Kanazawa K, Nomura M, et al. Ppp6c deficiency accelerates K-rasG12D - induced tongue carcinogenesis. Cancer Med. 2021;10(13):4451-4464.
8. Ohama T. The multiple functions of protein phosphatase 6. Biochim Biophys Acta Mol Cell Res. 2019;1866(1):74-82.
9. Stefansson B, Brautigan DL. Protein phosphatase 6 subunit with conserved Sit4-associated protein domain targets IκBε. J Biol Chem. 2006;281(32):22624-22634.
10. Kajino T, Ren H, Iemura S, et al. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J Biol Chem. 2006;281(52):39891-6.
11. Ziembik MA, Bender TP, Larner JM, Brautigan DL. Functions of protein phosphatase-6 in NF-kappaB signaling and in lymphocytes. Biochem Soc Trans. 2017;45(3):693-701.
12. Cho E, Lou HJ, Kuruvilla L, et al. PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK. Cell Rep. 2021;34(13):108928.
13. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-263.
14. Bonilla X, Parmentier L, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016;48(4):398-406.
15. Kanazawa K, Kishimoto K, Nomura M, et al. Ppp6c haploinsufficiency accelerates UV- induced BRAF(V600E)-initiated melanomagenesis. Cancer Sci. 2021;112(6):2233-2244.
16. Kato H, Kurosawa K, Inoue Y, et al. Loss of protein phosphatase 6 in mouse keratinocytes increases susceptibility to ultraviolet-B-induced carcinogenesis. Cancer Lett. 2015;365(2):223-228.
17. Hayashi K, Momoi Y, Tanuma N, et al. Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA. Oncogene. 2015;34(35):4647-4655.
18. Kudo K, Nomura M, Sakamoto Y, et al. Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer. FEBS Lett. 2020;594(9):1379-1388.
19. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. journal, North America. 2011;9 http://journal.embnet.org/index.php/embnetjournal/article/view/200/479
20. Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics. 2011;27(6):863-4.
21. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105-11.
22. Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA- Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511-5.
23. Draghici S, Khatri P, Tarca AL, et al. A systems biology approach for pathway level analysis. Genome Res. 2007;17(10):1537-45.
24. Morita M, Sato T, Nomura M, et al. PKM1 confers metabolic advantages and promotes cell- autonomous tumor cell growth. Cancer Cell. 2018;33(3):355-367.
25. DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379-400.
26. Roskoski RJ. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacol Res. 2019;142:151-168.
27. Caldwell AB, Cheng Z, Vargas JD, et al. Network dynamics determine the autocrine and paracrine signaling functions of TNF. Genes Dev. 2014;28(19):2120-33.
28. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178-196.
29. Kodama M, Oshikawa K, Shimizu H, et al. A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat Commun. 2020;11(1):1320.
30. Liberti M, Locasale JW. The Warburg Effect: How does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211-218.
31. Rupert JE, Narasimhan A, Jengelley DHA, et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J Exp Med. 2021;218(6):e20190450.
32. Sartori R, Romanello V, Sandri M. Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat Commun. 2021;12(1):330.
33. Agustsson T, Rydén M, Hoffstedt J, et al. Mechanisms of increased lipolysis in cancer cachexia. Cancer Res. 2007;67(11):5531-5537.
34. Ogoh H, Tanuma N, Matsui Y, et al. The protein phosphatase 6 catalytic subunit (Ppp6c) is indispensable for proper post-implantation embryogenesis. Mech Dev. 2016;139:1-9.
35. Guerra C, Schuhmacher AJ, Cañamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11(3):291-302.
36. Goradel NH, Najafi M, Salehi E, et al. Cyclooxygenase-2 in cancer: A review. J Cell Physiol. 2019;234(5):5683-5699.
37. Chuvin N, Vincent DF, Pommier RP, et al. Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRAS G12D-driven Pancreatic Tumorigenesis. Cell Mol Gastroenterol Hepatol. 2017;4(2):263-282.
38. Hotz B, Arndt M, Dullat S, Bhargava S, Buhr H-J, Hotz HG. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res. 2007;13:4769–4776.
39. Rasheed ZA, Yang J, Wang Q, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010;102:340– 351.
40. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediator, signaling, and metabolic pathway. Cell Metab. 2012;16(2):153-166.
41. Poulia KA, Sarantis P, Antoniadou D, et al. Pancreatic Cancer and Cachexia-Metabolic Mechanisms and Novel Insights. Nutrients. 2020;12(6):1543.
42. Talbert EE, Cuitiño MC, Ladner KJ, et al. Modeling Human Cancer-induced Cachexia. Cell Rep. 2019;28(6):1612-1622.e4.
43. Kordes M, Larsson L, Engstrand L, Löhr J-M. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br J Cancer. 2021;124(10):1623-1636.
44. Argilés JM, Busquets S, Stemmler B, et al. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754-62.
45. Qin C, Yang G, Yang J, et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 2020;19(1):50.
46. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47(D1):D941-947.
47. Wu N, Liu X, Xu X, et al. MicroRNA-373, a new regulator of protein phosphatase 6, functions as an oncogene in hepatocellular carcinoma. FEBS J. 2011;278(12):2044-2054.
48. Fujiwara N, Shibutani S, Sakai Y, et al. Autophagy regulates levels of tumor suppressor enzyme protein phosphatase 6. Cancer Sci. 2020;111(12)4371-4380.
49. Piffoux M, Eriau E, Cassier PA. Autophagy as a therapeutic target in pancreas cancer. Br J Cancer 2021;124(2):333-344.
50. Mann KM, Ying H, Juan J, et al. KRAS-related proteins in pancreatic cancer. Pharmacol Ther. 2016;168:29-42.
51. Westermarck J. Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back. FEBS J. 2018;285(22):4139-4145.
52. Leonard D, Huang W, Izadmehr S, et al. Selective PP2A enhancement through biased heterotrimer stabilization. Cell. 2020;181(3):688-701.
53. Mazhar S, Taylor SE, Sangodkar J, Narla G. Targeting PP2A in cancer: Combination therapies. Biochim Biophys Acta Mol Cell Res. 2019;1866(1):51-63.
論文の公開元へ
